Intensity Therapeutics reports 2024 net loss of $16.3M; cash $2.6M; trial enrollment ongoing

INTENSITY THERAPEUTICS, INC.

Net loss of $16.3M for FY2024 vs $10.5M in 2023; R&D expenses rose to $10.5M from $4.8M.
Cash and cash equivalents total $2.6M as of December 31, 2024.
INVINCIBLE-3 (Phase 3 sarcoma) has 32 sites contracted, 25 patients screened; enrollment expected by first half 2026.
INVINCIBLE-4 (Phase 2 TNBC) has 8 Swiss sites activated, several patients treated; enrollment expected end Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.